FCN News / April 30, 2026 First Choice Neurology is proud to celebrate a remarkable achievement within its leadership team.

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. "The ...

Test your knowledge on neurology research presented at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies -- outcomes not previously observed in SPS ...

Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, ...

Myasthenia gravis is a B-cell and antibody-mediated autoimmune neuromuscular disease that causes muscle weakness and fatigue, and patients may experience difficulty speaking, chewing, swallowing, or ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the presentation of data from its Phase 3 ...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies - outcomes not previously observed in SPS ...